Abstract:Highly immunogenic cancers such as malignant melanoma are capable of inexorable tumor growth despite the presence of antitumor immunity. Thus, only a restricted minority of tumorigenic malignant cells may possess the phenotypic and functional characteristics needed to modulate tumor-directed immune activation. Here we provide evidence supporting this hypothesis. Tumorigenic ABCB5(+) malignant melanoma initiating cells (MMICs) possessed the capacity to preferentially inhibit IL-2-dependent T-cell activation and to support, in a B7.2-dependent manner, induction of CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs). Compared with melanoma bulk cell populations, ABCB5(+) MMICs displayed lower levels of MHC class I, aberrant positivity for MHC class II, and lower expression levels of the melanoma-associated antigens MART-1, ML-IAP, NY-ESO-1, and MAGE-A. Additionally, these tumorigenic ABCB5(+) subpopulations preferentially expressed the costimulatory molecules B7.2 and PD-1, both in established melanoma xenografts and in clinical tumor specimens. In immune activation assays, MMICs inhibited mitogen-dependent human peripheral blood mononuclear cell (PBMC) proliferation and IL-2 production more efficiently than ABCB5(-)melanoma cell populations. Moreover, coculture with ABCB5(+) MMICs increased the abundance of Tregs, in a B7.2 signaling-dependent manner, along with IL-10 production by mitogen-activated PBMCs. Consistent with these findings, MMICs also preferentially inhibited IL-2 production and induced IL-10 secretion by cocultured patient-derived, syngeneic PBMCs. Our findings identify novel T-cell modulatory functions of ABCB5(+) melanoma subpopulations and suggest specific roles for these MMICs in the evasion of antitumor immunity and in cancer immunotherapeutic resistance. Cancer Res; 70(2); 697-708. (C)2010 AACR.

Supplementary Methods and Materials from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 1 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 3 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Modulation Of T-Cell Activation By Malignant Melanoma Initiating Cells

Data from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Interaction of Molecular Alterations with Immune Response in Melanoma

Supplementary Methods and Materials, Figure Legend from ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM

Supplementary materials and methods from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA

Supplementary materials and methods from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma

Modulation of innate immunity in the tumor microenvironment

Supplementary Materials from Targeting DNA Damage Response Promotes Antitumor Immunity Through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Supplemental Materials and Methods from Targeting TAZ-Driven Human Breast Cancer by Inhibiting a SKP2-p27 Signaling Axis

Supplementary Methods from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Supplementary Methods, Figures 1-15 from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of Ciap-1/2 and XIAP

Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy

Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment